Chromosome 3p abnormalities and allele loss are frequent in lung and breast cancers, and several lung cancer cell lines exhibit homozygous deletions of 3p indicating potential sites of tumor suppressor genes at regions 3p21.3, 3p14.2 and 3p12. We have identi®ed and characterized a new 3p21.3 homozygous deletion in a breast cancer cell line and the primary tumor that overlaps those previously described in small cell lung cancer (SCLC). This homozygous deletion is approximately 220 kb in length and represents a somatically acquired change in the primary breast cancer. Cloning and sequencing of the breakpoint demonstrated that this resulted from an interstitial deletion and precisely pinpoints this deletion within the three SCLC homozygous deletions previously reported. This deletion signi®cantly narrows the minimum common deleted region to 120 kb and is distinct from the previously reported region that suppresses tumor formation of the murine A9 ®brosarcoma cells. These ®ndings suggest that a common homozygous deletion region on 3p21.3 is important in both lung and breast cancers. It is likely that this very well characterized region either contains one tumor suppressor gene common to both tumor types or two closely linked tumor suppressor genes speci®c for each tumor.
Introduction
Deletions and allele loss frequently aect chromosome region 3p in both SCLC and non-small cell lung cancer (NSCLC), implying the existence of a tumor suppressor gene (TSG) or genes in this region. Cytogenetic evidence ®rst showed a consistent deletion on the short arm of chromosome 3 and loss of heterozygosity (LOH) was subsequently con®rmed by restriction fragment length polymorphism (RFLP) analysis and allelotyping by microsatellite markers (Kok et al., 1987; Naylor et al., 1987; Whang-Peng et al., 1982) . These analyses detected the deletion in nearly all SCLCs and about three quarters of NSCLC, although the identity of such a gene(s) remains elusive despite intensive investigation. So far, several distinct 3p regions have been identi®ed as showing frequent allele loss: 3p25-26, 3p21.3-22, 3p14, and 3p12 (Hibi et al., 1992) .
Furthermore, homozygous deletions have been found in the 3p21.3 region in three SCLC cell lines, NCI-H740, NCI-H1450 and GLC20 (Daly et al., 1993; Kok et al., 1994) , in the 3p21.3-22 region in ®ve SCLC cell lines including ACC-LC-5 (Yamakawa et al., 1993) , in the 3p14.2 FHIT/FRA3B region in six lung cancer cell lines Ong et al., 1997) and in the 3p12 region in one SCLC cell line, U2020 (Drabkin et al., 1992; Latif et al., 1992) . These deletions when originally identi®ed were large with estimated sizes of 1500 kb for NCI-H740, 800 kb for ACC-LC-5 (Murata et al., 1994) and about 8 Mb for U2020. This implied a requirement of further massive eorts for positional cloning of TSGs in these regions. Therefore, new homozygous deletions or rearrangements have been sought to narrow down these target regions. In addition, homozygous deletions of 3p21.3 were also found in three uncultured lung tumors bȳ uorescence in situ hybridization analysis , indicating that the deletion is not an event of cell culture but appears critical for primary cancer development.
We have studied in detail several candidate 3p TSGs. One candidate gene in the 3p25 region, the von Hippel-Lindau (VHL) tumor suppressor gene, is only rarely mutated in lung cancer (Sekido et al., 1994) . Another candidate gene FHIT, which spans the FRA3B fragile site at 3p14.2, is associated with homozygous deletions in lung cancer and with cancer-related FHIT cDNA splicing aberrations Sozzi et al., 1996) . However, in nearly all cancers a wild-type FHIT transcript is also expressed, making this gene dierent from other known TSGs . A reasonable interpretation of FHIT abnormalities is that they represent alterations in the FRA3B fragile site (Boldog et al., 1997; Fong et al., 1997) . The H740 homozygous deletion region at 3p21.3 has also been extensively studied by us and others, including construction of a cosmid contig covering 700 kb , identi®cation of new genes including 3pK (Sithanandam et al., 1996) , SKMc15 (Latif et al., 1997) , Semaphorin A(V) (proposed symbol SEMAA) , and Semaphorin IV (also called Sema III/F and proposed symbol SEMAK) (Roche et al., 1996; Sekido et al., 1996; Xiang et al., 1996) , and mutational analysis of these genes. However, these genes have been shown not to have a signi®cant number of mutations in lung cancer although some genes such as Semaphorin A(V) seemed to be downregulated dramatically in SCLC, which may indicate that epigenetic changes are involved in inactivation of the gene .
Deletions of 3p have been demonstrated in breast cancer by cytogenetic and LOH studies, indicating several regions (3p24-26, 3p21.3, and 3p13-14. 3) involved in breast cancer (Chen et al., 1994; Devilee et al., 1989; Pandis et al., 1995; Pandis et al., 1993; Sato et al., 1991) . LOH at 3p21.3 was initially shown in seven of the 17 informative cases of 28 primary tumors with the D3F15S2 (previously called DNF15S2) probe (Devilee et al., 1989) . A homozygous deletion was identi®ed in a primary breast cancer with the D3S2 probe which maps to 3p14.3-21.1 (Buchhagen et al., 1994) . The FHIT gene was also demonstrated to be abnormal in breast cancer Hayashi et al., 1997; Negrini et al., 1996) . In addition, LOH was detected in morphologically normal lobules adjacent to breast cancers and the most frequent aberration was at chromosome region 3p22-25 (Deng et al., 1996) . This evidence encouraged us to screen breast cancers for deletions in the 3p21.3 region, leading us to identify and characterize a new homozygous deletion in a breast cancer cell line recently started by us.
Results

Detection of a homozygous deletion in a breast cancer cell line
Based on the evidence that there are three SCLC overlapping homozygous deletions on 3p21.3 and that breast cancers also show frequent LOH at the 3p21.3 locus, we performed studies to detect genomic DNA abnormalities in 26 breast cancer cell lines. Selected PCR primers, localized to the H740 deletion region, were tested for detection of homozygous deletions, and Southern blot analyses were performed to survey the H740 homozygous deletion region to con®rm PCR data as well as to independently detect abnormalities.
One cell line among 26 breast cancers, HCC1500, was identi®ed to have a homozygous deletion by both PCR and Southern blot analysis. A probe synthesized from the LUCA2 gene clone (GenBank #U09577) located in cosmid LUCA#13 (GenBank #AC002455) detected a homozygous deletion in HCC1500 but not in the corresponding stromal cell line, HMS73 ( Figure  1b) . Likewise, the cDNA fragment of the LUCA1 gene (Genbank #U03056) detected rearranged bands in HCC1500 DNA, which were con®rmed not to be a polymorphism since three dierent restriction enzymes of EcoRI, HindIII, BamHI digestion showed abnormal bands in only HCC1500 DNA but not in the stromal cell line DNA (Figure 1c ). Comparing the restriction map of cosmid LUCA#13, these data suggested that the telomeric breakpoint of HCC1500 is in cosmid LUCA#13, 4.2 kb upstream of the LUCA1 gene ( Figure 2a ). On the other hand, the 3pK gene (GenBank #U09578) (Sithanandam et al., 1996) which resides centromeric to the HCC1500 deletion and SKMc15 (GenBank #U09585) (Latif et al., 1997) and Semaphorin A(V) (GenBank #U28369) , which both reside telomeric to the deletion are intact (Figure 2a ). Furthermore two more distant markers¯anking the HCC1500 homozygous deletion, D3S1235 (MFD93) (centromeric) and D3F15S2 (telomeric), were intact in the HCC1500 DNA ( Figure 2a ).
Cloning the breakpoint of the homozygous deletion
To determine if the HCC1500 homozygous deletion is due to a simple interstitial deletion or a translocation with deletion, we cloned the breakpoint of the HCC1500 homozygous deletion. We designed additional primers based on the sequence of cosmids LUCA#4 (GenBank #Z74019), #6 (GenBank #Z84493), #8 (GenBank #Z84495), #9 (GenBank #Z75743), and #10 (GenBank #Z75742) and tested HCC1500 in order to narrow down the site of the centromeric breakpoint ( Figure 2a ). These results suggested that the centromeric breakpoint of HCC1500 exists in cosmids LUCA#6 and that the centromeric breakpoint is *150 kb apart from the 3pK gene since HCC1500 DNA was intact by PCR for the primer set of the cosmid LUCA#4 but deleted for the primer sets of the cosmid LUCA#8, #9 and #10 (data not shown). Next, we designed four additional sets of primers in cosmid LUCA#6 and tested them by PCR and Southern blot analysis of HCC1500 DNA. Southern blot analysis of the primer set (6A) detected abnormal bands on HCC1500 which were identical to the bands detected by the LUCA1 gene cDNA probe which is 220 kb telomeric of the cosmid LUCA#6 (Figure 1a and c). This suggests that HCC1500 has a simple interstitial deletion about 220 kb, and approximately established the ends of the deletion on the cosmid contig. Although additional high density screening by Southern blot and PCR analysis covering the HCC1500 deletion region were performed for the other 25 breast cancer cell line DNAs, no other deletions or abnormalities were detected (data not shown).
To clone the breakpoint of HCC1500, we designed a sense primer, L6pr10516s, from cosmid LUCA#6 and an antisense primer, L13pr24261as, from cosmid LUCA#13 and performed PCR to see if we could amplify across the junction. A novel 2.2 kb PCR fragment was ampli®ed only from HCC1500 DNA but not from the stromal and other cell line DNAs (data not shown). This fragment was subcloned into pGEM-T plasmid and sequenced (Figure 2b ). The sequence identi®ed the fusion junction and precisely pinpointed the breakpoints centromerically and telomerically in the cosmid contig.
The 220 kb deletion of HCC1500 is a somatic event occurring in the primary tumor According to the breakpoint sequence, additional primers, L6pr11245s and L13pr22984as, were synthesized to amplify a 260 bp fragment across the HCC1500 breakpoint and tested on DNAs extracted from the patient's primary tumor tissue and corresponding non-malignant breast tissue as well as the cell line DNAs. Figure 3a shows that the chimeric PCR product was ampli®ed in HCC1500 DNA and the primary tumor DNA but not in the stromal cell line DNA or the non-malignant breast tissue DNA. Furthermore, Southern blot analysis of the primary tumor DNA and the non-malignant breast tissue DNA con®rmed the identical pattern of the changes between the cell line DNA and the primary tumor DNA (Figure  3b ). These studies demonstrated that the 220 kb The primary tumor specimen used to prepare bulk DNA was contaminated with normal cells. Thus the Southern blot gave bands hybridizing to both the normal germline fragments as well as the rearranged novel fragments (Figure 3b ). To determine if only the mutant or both mutant and wild-type allele were in the tumor cells, we employed microdissection technique followed by PCR assay to avoid contamination with normal cells. Precisely microdissected specimens were obtained from the paran-embedded primary invasive breast carcinoma and accompanying intraductal carcinoma, histologically normal lobules and ductal breast epithelia ( Figure 4A ). The intraductal carcinoma cells were contiguous to histologically normal ductal cells and contamination in the microdissection could not be avoided ( Figure  4A, c and d) . Multiplex PCR was performed with a primer set of L6pr11245s and L13pr22984as amplifying the chimeric 260 bp fragment and a primer set of L12pr35s and L12pr36as amplifying a control normal 179 bp fragment which resides in the 220 kb homozygous deletion region. The results showed that the 260 bp chimeric band was detected in the invasive cancer, while the wild-type band was weak or absent, indicating loss of the wild-type allele ( Figure 4B lanes 7 and 8) . Of interest, both the 260 bp chimeric band and the 179 bp normal band detecting the deletion were ampli®ed in the intraductal breast carcinoma ( Figure 4B lane 6) . This could be explained either by contamination with normal ductal cells or by retention of the wild-type allele in the intraductal component. Several samples of adjacent histologically normal cells showed only the normal band, which again con®rmed that the interstitial deletion was tumor-speci®c.
Discussion
The present data show that one breast cancer cell line, HCC1500, and its primary tumor have a 220 kb homozygous deletion overlapping the three common homozygous deletions in SCLC cell lines, NCI-H740, NCI-H1450 and GLC20, which themselves have an estimated common region around 370 kb (Kok et al., 1994; Wei et al., 1996) . The homozygous deletion of HCC1500 has now narrowed the common region of deletion to 120 kb, which suggests that lung and breast cancers might share the same TSG for the 3p21.3 locus. Alternatively, it is possible that there are two closely linked TSGs, one for lung cancer and the other for breast cancer. While the three homozygous deletions in SCLC were demonstrated only in the established tumor cell lines, the 220 kb deletion of HCC1500 provides clear evidence that this change was acquired somatically and existed in the primary tumor. These results, along with those of Todd et al. (1997) , provide strong support that this region is critical for tumor development.
Cloning and sequencing of the breakpoint demonstrated that this resulted from an interstitial deletion. We performed a BLAST search with the fusion junction sequence but no high quality matches were found. It will be interesting to compare other fusion junctions from cancer related interstitial deletions or translocations to see if there is a common theme. This could provide a clue to the enzymatic mechanism generating these common changes found in cancer.
The telomeric deletion of HCC1500 is 4.2 kb upstream of the LUCA1 gene, which potentially could involve 5' regulatory sequence of LUCA1. It appears to exclude other candidate TSGs in the contig such as SKMc15, Semaphorin A(V), GNAI2, GNAT1 and Semaphorin IV (also called SemaIII/F) residing in the telomeric region of the H740 homozygous deletion. This region is also contiguous to, but quite distinct from that identi®ed by a transfection assay using a P1 clone into murine A9 cells (Todd et al., 1996) . This region is much further telomeric from the breakpoint of the HCC1500 homozygous deletion (Todd et al., 1996) . However, this P1 clone did suppress tumorigenicity, albeit in mouse cells, providing functional evidence of a TSG in this distal region. It will be necessary to perform similar functional tests in the HCC1500 deletion region. The centromeric breakpoint of the HCC1500 deletion was about 150 kb centromeric from the 3pK gene, which was found not to have mutations (Sithanandam et al., 1996) . In the 120 kb common deletion region, we have identi®ed eight distinct genes so far including LUCA1, LUCA2, fus1, 123F2, BLU2, 101F6, PL6 and Gene 26, all of which now require detailed mutational analysis in breast and other cancers as well as lung cancers. It is of course possible that more than one TSG exists in this region, one of which is important for breast and the other for lung cancer. Materials and methods
Cell lines
Twelve breast cancer cell lines were established in our lab (pre®x HCC for Hamon Center for Therapeutic Oncology Research): HCC38, HCC712, HCC1008, HCC1187, HCC1395, HCC1428, HCC1500, HCC1599, HCC1739, HCC1937, HCC1954 and HCC2157. The HCC1500 cell line was established from a surgical specimen of a ductal adenocarcinoma resected from a 32-year-old black female. The TNM classi®cation was stage IIB with four of 24 axillary nodules positive for metastatic tumor. HMS73, a cell strain of normal mammary stromal cells was 
Southern blot analysis
High molecular weight DNAs were extracted by standard methods (Sambrook et al., 1989) . Five mg of DNAs, digested with appropriate restriction endonucleases (Gibco BRL), were electrophoresed in 0.7% agarose gels, transferred to Hybond N + membranes (Amersham), hybridized with 32 P-labeled probes synthesized with random primers and subjected to autoradiography after washing according to the company protocol (Amersham). Reprobing of the same membranes was performed after stripping of previous probes.
PCR analysis
Primers were designed either from sequences of cDNA clones we isolated in the 3p21.3 homozygous deletion region or from genomic sequences of the 700 kb cosmid and P1 clone contig . This contig is being sequenced jointly by The Genome Sequence Center at Washington University, St Louis and The Sanger Centre, Hinxton, UK, and most of the sequences have been deposited in GenBank. Primers were synthesized based on the sequences of the cosmids and the key primer sets are given below while the rest are available upon request. The primer set (6A) for Southern blot probe (Figure 1a ) designed from cosmid LUCA#6 is L6pr11s, 5'-AAGGA-CAACTTTGTCACCAG-3' and L6pr12as, 5'-CAAGGA-GAGATACAAAGACTC-3'. The primer set for cloning the 2.2 kb fragment of the HCC1500 breakpoint is L6pr10516s, 5'-AGGTGGAGATTCTGCAGAAG-3' from cosmid LUCA#6 and L13pr24261as, 5'-AGCAGTCTA-CAGCCTGAGAC-3' from cosmid LUCA#13. The primer set for demonstrating the 260 bp novel fusion junction fragment of the HCC1500 breakpoint is L6pr11245s, 5'-TCTCAGCACTTGAGGCATAG-3' from cosmid LUCA#6, and L13pr22984as, 5'-TGACAGAGCAAGAC-TCCATCTG-3' from cosmid LUCA#13. The primer set from cosmid LUCA#12 for detecting the normal 179 bp fragment in the homozygous deletion region for microdissected samples is L12pr35s, 5'-CTGTCCTTTACCC-TACCCTT-3', and L12pr36as, 5'-AGGAGTGAGAAGA-GGTATGAA-3'.
Some PCR products were further puri®ed and used as probes for Southern blot analysis. The 2.2 kb PCR product covering the breakpoint of the interstitial deletion of HCC1500 was subcloned into pGEM-T vector (Pharmacia), pHC1500-2.2, and bidirectionally sequenced by automated cycle sequencing (ABI).
Microdissection and DNA extraction
Microdissection and DNA extraction were performed from microslides as previously described (Hung et al., 1995) . Precisely identi®ed areas of the paran-embedded primary invasive carcinoma and accompanying intraductal carcinoma, histologically normal breast lobules and ductal breast epithelia were microdissected under microscopic visualization. Lymphocytes from a normal axillary lymph node were also obtained. After DNA extraction, 5 ml of the digested samples, containing DNA from at least 100 cells, were used for each multiplex PCR.
